

**Towards a new classification
of contraceptive methods for a better
sustainable development.
A global bioethical approach**

**Hacia una nueva clasificación
de los métodos anticonceptivos
para un mejor desarrollo sostenible.
Un enfoque bioético global**

Maroun BADR*

UNESCO Chair in Bioethics and Human Rights, Rome, Italy

<https://doi.org/10.36105/mye.2025v36n2.05>

Abstract

Sustainable Development Goals (SDG) 3.7 and 5.6 aim to achieve universal access to sexual and reproductive health services and rights by 2030. These services include family planning, in particular contraception. According to UN statistics, the use of modern contraceptive methods far exceeds that of traditional methods. However, this division between “modern” and “traditional” seems to have several inconsistencies. Based on a global bioethical approach, this article aims to propose a new classification of contraceptive methods. The need for

* PhD in Bioethics, Research Scholar. UNESCO Chair in Bioethics and Human Rights, Rome, Italy. E-mail: info@unescobiochair.org <https://orcid.org/0000-0001-9378-6273>

Reception: 26/10/24 Acceptance: 12/12/24

complete and accurate information on family planning, and the involvement of both partners in contraceptive decisions, are key takeaways.

Keywords: contraception, family planning, women's health, gender equality.

Introduction

Sustainable Development Goal (SDG) 3.7 states that “by 2030, ensure universal access to sexual and reproductive health care services, including family planning” (1). These reproductive health services (2) primarily include contraceptive methods. UN statistics (3, p. 6) estimate that, in 2021, 77% of women of reproductive age (15-49) use modern methods, 8% use traditional method and 16% have an unmet need for family planning.¹ The most commonly used methods (3, p. 17) are female sterilization (22.9%), the male condom (21.8%), the IUD (16.8%) and the pill (15.7%). Although there are several ways to classify contraceptive methods (4, p. 291), inconsistencies remain “in the definition and criteria for classifying contraceptive methods as ‘modern’ contraceptives” (5, p. 31), as asserts the World Health Organization’s (WHO) Department of Reproductive Health and Research. Despite these inconsistencies, UN texts, especially those of the Agenda 2030 and those that refer to it, use the classification of two categories: modern and traditional. After presenting what this classification entails [1], this article aims to analyze in detail its ambiguities [2] and to propose a new classification of contraceptive methods [3] based on a global bioethical approach. This corresponds to some of the points highlighted in the Universal Declaration on Bioethics and Human Rights (UDBHR) (6) since “the principles recognized in the UDBHR share a common base and level of support to attain a global bioethics which evolves, is flexible

¹ As it is mentioned in the document, “numbers may not add up to 100 due to rounding”.

and capable of helping solve bioethical problems as well as promoting equality and respect for human rights” (7, p. 72).

1. Contraceptive methods according to UN texts

1.1. *The classification*

According to the United Nations Department of Economic and Social Affairs reports, *Family Planning and the 2030 Agenda for Sustainable Development* (8, p. 21) and *World Family Planning 2022* (3, p. 4), and the who report (9, p. 301), *Family Planning: A Global Handbook for Providers*, modern methods include: oral contraceptive pills (combined/estrogen-progestin and progestin-only), injectables (combined or progestogen-only), transdermal contraceptives (implant or patch), vaginal ring (combined or progestogen-only), vaginal barrier methods (female condom, diaphragm, cervical cap, spermicidal foam, jelly, cream and sponge), intra-uterine devices/IUD (copper or levonorgestrel), the lactational amenorrhea method (LAM), male condom, male (vasectomy) and female sterilization (tubal ligation), and emergency contraception.

Traditional methods include coitus interruptus (withdrawal), periodic sexual abstinence based on the Fertility awareness-based methods² (FABMs) such as Calendar-based methods³ (rhythm method/Knaus-Ogino method and Standard Days Method) and Symptoms-based methods (cervical secretions, basal body temperature, TwoDay method, Billings Ovulation Method and Symptothermal method). In addition, there are other traditional methods [“douching, prolonged abstinence, gris-gris, incantation, medicinal plants, abdominal massage and other local methods” (10, p. 24)].

² The three UN documents on which this research is based do not mention the Creighton Model in the list of Fertility awareness-based methods.

³ It is important to stress that Calendar based methods should not be classified as FABMs, since the woman does not observe the cycle, but makes calculations based on previous cycles, or counts the days.

1.2. *Contraceptive prevalence*

Thus, SDG's indicator 3.7.1 defines contraceptive prevalence as "the percentage of women who are currently using, or whose partner is currently using, at least one method of contraception, regardless of the method used" (11, p. 2). According to UN statistics (12), worldwide figures have risen from 18.9% in 1970 to 58.8% in 2023. In Europe and North America, the figures rose from 34.8% to 63.4% over the same period.

Two points deserve special attention. First, the definition of contraceptive prevalence is limited solely to the use of modern family planning methods, excluding traditional methods. Second, there are several reasons for the difference in contraceptive prevalence:

- a) 65% of women, in developing countries, do not use modern methods (13) or prefer using the so-called traditional or natural methods (14).
- b) According to the WHO (15), unintended pregnancies (UIPs) are associated with a lack of family planning and difficulties in accessing modern methods. The *Contraception Policy Atlas* (16) identifies three types of accessibility.
 - a. Access to supplies/coverage: coverage of some contraceptives by the national health system, special coverage for young and vulnerable groups, and coverage for at least one Long-Acting Reversible Contraceptive (LARC) by the national health system.
 - b. Access to counseling including the coverage of counseling (level of available, accessible, and affordable consultation, need for third-party consent, Legal status (marital, citizenship) is not a barrier) and prescription requirements (availability of emergency contraception and hormonal contraceptives available without prescription).
 - c. Availability of online information that includes type of online information, information coverage (number of contraceptives listed, info on costs of contraceptives and info

where to get contraceptives) and user friendliness (regional or minority language included, Web design, discoverability of the website online).

- c) According to the WHO (15), two-thirds of women have stopped using contraception because of “fear of side effects”.

These elements highlight the ambiguities and inconsistencies surrounding the classification, still used in UN texts today.

2. Classification ambiguities and inconsistencies

The International Conference on Population and Development (ICPD) (17) states that only complete information can guarantee women an “adequate development of responsible sexuality [...] to achieve good sexual health and exercise their reproductive rights and responsibilities” (§ 7.36). Complete information also means clear definition. However, the WHO does not define a modern contraceptive method. As a result, the division of contraceptive methods into two groups, modern and traditional, remains an imprecise one due to the following ambiguities: temporal/historical context [2.1], effectiveness [2.2], safety [2.3], environmental impact [2.5] and gender equality [2.4]. The first two ambiguities were briefly highlighted by M. P. R. Festin *et al.*, (4, p. 290).

2.1. Temporal/historical context

The characters “modern” and “traditional” naturally evoke a temporal axis: modern is recent and traditional is ancient. However, classifying contraceptives according to the concept of time discredits such a classification, since certain modern methods are older than certain traditional methods, and vice versa.

A chronological overview (18–20) allows us to place the appearance of the first models of what we know today (date in parentheses)

in relation to the earlier use of these methods. The use of the condom (1880), spermicides (1906) and the IUD (1928) dates from at least 3000 BC. The equivalent use of the diaphragm (1880), the cervical cap (1830) and the female condom (1908) dates from the 2nd century BC. Contraceptive injections date from 1922. Basal body temperature and Knaus-Ogino method date from the 1930s. The pill was introduced in 1955. Billings Ovulation Method dates from the 1960s-1970s. The Creighton Model FertilityCare System (21) dates from 1976. Although classified as modern (8, p. 21; 10, p. 24) in UN texts and developed between 1980 and 1995, LAM method dates back to ancient Egypt (22, p. 44). The implant was invented in 1983. Marquette method (23) dates from 1999. Standard Days Method dates from 2001. The TwoDay method, the vaginal ring and the patch date from 2004. The Fertility Education and Medical Management method (FEMM) was created in 2012 (24) and the FemTech⁴ (25) was invented in 2016.

2.2. *Effectiveness*

Modernity can also be approached from the point of view of effectiveness especially to avoid UIPs and to reduce the abortion rate, as claimed by the ICPD (§ 7.10, 7.13, 7.24, 8.25, 106.k), the Beijing Declaration (26, § 72.c, 72.l, 72.o, 106.k, 109.i), and Agenda 2030 SDG 3.7 and 5.6. However, many studies have shown that 48% to 73.4% of women who had an UIP were using contraception (27,28). Statistics from the Guttmacher Institute (29) show that 30% of UIPs are due to contraceptive failure methods. In this context, what are the criteria used to promote modern methods as effective and other traditional methods as less effective?

The effectiveness of contraceptive methods is measured by the Pearl Index (PI), a statistical index that represents the number of pregnancies observed per 100 couples during the first year of optimal use

⁴ FemTech refers to products, software and digital health technologies used particularly to improve women's health.

of any contraceptive method. The index presents theoretical effectiveness, which should be compared with practical effectiveness. The latter is obtained on a sample basis, including women and couples who did not use contraception because they forgot to take the pill, used condoms incorrectly or did not pay attention to the ovulation cycle.

The who's contraceptive effectiveness table (9, p. 415) is a combination of two studies: the first is carried out in the USA by J. Trussel and A. Aiken (30, pp. 844-845) and the second is carried out in developing countries by C. Polis et al. of the Guttmacher Institute (29). According to this table, modern methods have a higher effectiveness than traditional ones including FABMs methods.

Nevertheless, it is inconsistent to rely on the PI to assess contraceptive effectiveness, to distinguish between “modern” and “traditional” methods, and to promote modern methods as more reliable. This is due to the mode of action of each of these two categories of contraceptives. On the one hand, modern methods have a rapid effect, which varies between the time of use and 7 days after the first use or the start of menstruation. The study to measure their efficacy according to the PI must be conducted during the first year of contraceptive use. On the other hand, since there is no immediate intermediate element (mechanical or hormonal), FABMs are based on an observational protocol. Indeed, several studies have shown that the only condition allowing PI to be used correctly for FABMs is that the women chosen for the study had already been trained in one of these methods. The Symptothermal method (31) gave a result of 0.4 UIP per 100 women with abstinence on fertile days and 1.8 overall. Under the same conditions, the Billings Ovulation Method (32) showed an efficacy of 0.5 versus 2 for the IUD. The Marquette method (33) had a result between 2 and 6.8. Even “the efficacy of a contraceptive mobile application is higher than usually reported for traditional fertility awareness-based methods” (34).

In addition, it is important to note that contraceptive failure depends on a number of factors (35): a) the woman's age (the older the woman, the higher the failure rate), b) marital status (high rate among unmarried or cohabiting women), c) the economic level of

the country (more failures in poorer countries), and d) the interactions with medications taken at the same time as certain contraceptive methods (especially hormonal methods).

2.3. *Safety*

While the ICPD calls on states to “provide accessible, complete and accurate information about various family-planning methods, including their health risks and benefits, possible side effects” (§ 7.23 b) and while SDG 3 insists on protecting and promoting women’s health, the who states that two-thirds of women have stopped using modern contraception because of “fear of side effects” (15). The most used methods with significant risks include combined oral contraceptive (COC) pill [2.3.1], progestin-only contraception [2.3.2] and the copper IUD [2.3.3]. Some other risks are common to contraceptives [2.3.4] which can have also an environmental impact [2.3.5]. However, it is important to understand that the risks are not systematic. Their occurrence depends on many factors, such as genetic predisposition, lifestyle, etc.

2.3.1. *The Combined oral contraceptive pill*

COC have consequences on the psycho-neuro-endocrinological system such as: women’s perception of their choice of partner (36, pp. 102-144), reduced sexual desire (37), reduced orgasm due to reduced clitoral volume (38) (leading to increased pain during intercourse), depression (39), suicide attempts (40), post-partum depression (41), collateral hormonal effects (42, pp. 105-111), altered memory (43) in general, and topographical (44) and emotional memory (45) in particular, verb generation task (46), face recognition (47), alterations in hypothalamic and pituitary gland (48) and in fear-related brain morphology (49).

We can also note a hepatic overload due to the double passage in the liver (metabolization-distribution and metabolization-elimination)

leading to an overconsumption of micronutrients, consequently to a deficit of certain minerals, trace elements and vitamins, as in the case of the decrease of zinc which favours the early appearance of osteoporosis (50) and to bone turnover in young adult women. METHODS: Cross-sectional study. Blood and urine samples from non-users (-OCA; control; n=69, but also to an excess of copper and vitamin D (42, pp. 78-98; 51, pp. 60, 158-169).

In addition, certain proteins involved in blood clotting are altered (52), leading to venous thromboembolism (53) (phlebitis and pulmonary embolism) and arterial thromboembolism (stroke and myocardial infarction).

Other studies have highlighted the risks of autoimmune diseases, especially for women with a genetic predisposition, such as myocarditis (54), systemic lupus erythematosus (55), multiple sclerosis, Crohn's disease and interstitial cystitis (56).

What's more, the International Agency for Research on Cancer (IARC) classifies COC as Group 1 carcinogenic to humans (57, pp. 21, 35). Thus, women who use the pill have a higher risk of developing breast, cervical and liver cancer (57, pp. 283-293, 295-296) than women who do not use the pill.

2.3.2. Progestin-only contraception

The progestin-only pill can may cause unpredictable bleeding and the drospirenone-based micropill may increase the potassium levels in the blood, thereby increasing cardiovascular risks (42, pp. 181-182).

The etonogestrel-based implant carries thromboembolic risks (58), and other risks listed by the WHO (9, p. 133) including acne, mood changes, bleeding, headache, dizziness, nausea and abdominal pain.

The levonorgestrel IUD, particularly Mirena (59, pp. 15-16), can cause ectopic pregnancy (60-62), group A streptococcal sepsis (GAS), pelvic inflammatory disease, perforation, ovarian cysts, bleeding pattern, and vulvovaginitis.

Studies indicate a significant association between the use of the progestin-only injectable contraceptive, such Depot medroxyprogesterone acetate (DMPA), and an increased risk for acquisition and transmission of HIV-1. It is important to note that this contraceptive is commonly used in regions with high HIV-1 prevalence has a higher risk (63,64).

Macroprogestins (pill or injection), i.e. those in high doses, carry a major risk: intracranial meningioma (65,66).

The use of progestin-only contraceptives is also associated with a significant (20-30%) increase in the risk of breast cancer (67,68) and a delayed fertility (69).

2.3.3. Copper IUD

According to the WHO, women who use the copper IUD may be at risk of: prolonged and heavy monthly bleeding (9, p. 166) which can lead to anaemia (70,71), cramps, severe lower abdominal pain indicating either pelvic inflammatory disease or ectopic pregnancy, uterine perforation, high blood copper levels above the norm which could have serious consequences: “neurological symptoms such as depression, fatigue, irritability, excitation, and difficulty focusing are reported too. In most severe forms, copper toxicity leads to rhabdomyolysis, cardiac and renal failure, methemoglobinemia, intravascular hemolysis, hepatic necrosis, encephalopathy, and ultimately death” (72).

2.3.4. Other risks

Another rare but real risk is intrauterine pregnancy (59, p. 15) with an IUD (levonorgestrel or copper) which causes a higher rates of vaginal bleeding, chorioamnionitis and placental abruption, the risk of miscarriage and preterm delivery (73).

Progestin injections, implants and copper IUD cause also a significant weight changes (74).

2.4. *Environmental impact*

Since the SDGs interact with each other in a transversal way, it is important to note that modern contraceptive methods, as a fundamental element of family planning, also have a non-negligible environmental impact.

On the one hand, the production of certain mechanical contraceptives such as condoms and the copper IUD has a significant impact on global warming due to the pollution caused during their production (75–78), and on the health of living beings due to the toxic materials used in the process (79).

On the other hand, hormonal contraceptives considered to be endocrine disruptors (80, pp. 22, 76, 86) - especially those based on 17 α -Ethinylestradiol (EE2), have an impact on aquatic life [feminization (81), intersexuation (82), reproductive disruption (83–85) and extinction (86)] and on human life due to EE2 residues in water [prostate cancer (87,88), reduced masculine fertility (80,89,90), fetal growth and health problems such as hypo-plastic left heart syndrome and gastrochisis (91), disruption of fetal and neonatal testicular development (92), autism spectrum disorder (93,94)].

Based on all these facts, it makes sense to ask how modern contraceptive methods can be promoted in SDGs 3.7 and 5.6 when they negatively affect many others: SDG 2.1 (access to safe, nutritious and sufficient food while water and fish are polluted), SDG 6.3 (improve water quality by reducing chemical pollution while endocrine disruptors used) SDG 14.1 (reduce marine pollution which affects one of the most important sources of food: seafood), SDG3 (preservation of health especially women's), SDG 6.3 (quality drinking water), and SDG 13 (climate change while the production of some contraceptives has an impact on global warming).

2.5. *Gender equality*

As SDG 5 aims to achieve gender equality and empower all women, and since SDG 5.6 aims to “ensure universal access to sexual and

reproductive health and reproductive rights”, the 2030 Agenda 2030 has introduced indicator I 5.6.1 to analyze the proportion of women aged 15 to 49, in 57 countries, who make their own informed decisions about health care, contraceptive use and sexual relations. Furthermore, the United Nations Population Fund (UNFPA, United Nations sexual and reproductive health agency) points out that focusing on the promotion of female contraceptives without taking into account “men’s needs and knowledge [...] raises the human rights and ethical issue of gender equality” (95, p. 69). Indeed, the use of modern contraceptives raises two issues of equality.

On the one hand, studies have shown that many women are unaware of their partner’s views on contraceptive use (96). In addition, many men prefer to use traditional methods for three reasons: a) because they want to be involved in the decision (97); b) because they don’t know enough about the practical use of modern contraceptives (98); c) because they are afraid of the side effects the woman might suffer (99).

On the other hand, some may blame men for not using male contraception (100, p. 50) [hormonal (101–104), Heat-based contraception (105), non-hormonal contraception (106–108), reversible occlusive contraception (109–111) and immunotherapy contraception (112,113)]. In this regard, the ICPD has already encouraged the use of voluntary and appropriate male methods of contraception (§7.8).

From an equality perspective, this is an understandable criticism. However, there are three main barriers to progress in the development of male contraceptives: social constraints, according to which contraception is a woman’s business; the lack of economic competition due to the low success rate of male contraceptives; and men’s fear of suffering negative consequences (95, pp. 70-71; 100, p. 50). However, the physiological difference in gametogenesis between men and women was never mentioned, even though it plays a fundamental role in the way contraceptives work.

3. A new classification of contraceptive methods

Following analysis of the ambiguities and inconsistencies highlighted above, here is a new classification based on a global bioethical approach. Excluding two methods [3.1], three criteria [3.2] are used to divide the contraceptive methods into three categories [3.3].

3.1. Exclusion

Male contraceptive methods (other than condoms and vasectomy) are not included in this classification because of the lack of consensus, hindsight and scientific studies favoring their marketing.

Emergency contraception is also not included because of the ethical dilemmas surrounding its mode of action, which could be considered abortifacient when it prevents implantation of the embryo (114–116).

3.2. Criteria

The three criteria are purpose, scientificity and invasiveness.

- a) The **purpose criterion** allows contraceptive methods to be divided into two groups. On the one hand, there are contraceptive methods whose sole purpose is to prevent pregnancy. On the other hand, there are birth spacing methods based on knowledge of the female cycle, the body, how it functions and how to respect it. Two other criteria are used to divide the two groups into different categories.
- b) The **scientificity criterion** is based on scientific studies that follow precise observation protocols to verify the effectiveness of the methods.
- c) The **invasiveness criterion** is based on respect for physical integrity and must be examined at three different levels: the use (oral, vaginal or dermal) of a foreign element to the body that is likely to have risks and/or side effects, the surgical

intervention and the alteration of body function. Only one level is required for invasiveness.

3.3. Categories

By combining the criteria of scientificity and invasiveness, we can identify three categories:

- a) Popular Methods: non-scientific and non-invasive;
- b) Interfering Artificial Methods: scientific and invasive;
- c) Physiological Methods (with or without technical assistance: FemTech): scientific and non-invasive.

A. Groupe 1: Contraceptive purpose

a. Category 1: Non-scientific and non-invasive.

Popular methods

Coitus interruptus (withdrawal), douching, prolonged abstinence, gris-gris, incantation, medicinal plants, abdominal massage and other local methods.

B. Group 2. Birth spacing purpose

b. Category 2: Scientific and invasive.

Interfering artificial methods

Oral contraceptive pills (combined/estrogen-progestin and progestin-only), injectables (combined or progestin-only), transdermal contraceptives (implant or patch), vaginal ring (combined or progestin-only), vaginal barrier methods (female condom, diaphragm, cervical cap, spermicidal foam, jelly, cream and sponge), intra-uterine devices/IUD (copper or levonorgestrel), male condom, male and female sterilization (vasectomy and tubal ligation).

c. Category 3: Scientific and non-invasive.

Physiological methods (with or without technical assistance: FemTech)

- The natural method of ovulation inhibition: Lactational amenorrhea method (LAM).
- Statistical predictive methods: the Rhythm method/ Knaus-Ogino method and Standard Days method.
- Methods of Cycle Observation (MCO)⁵ (20, p. 11): Basal body temperature, TwoDay method, Billings Ovulation Method, Symptothermal method, Creighton Model Fertility-Care System, Marquette method and FEMM method.

4. Conclusion

The proposed new classification may have its limitations and further research is necessary to refine it. For this reason, it is not presented as the only answer to the ambiguities and inconsistencies in the division between modern and traditional methods. Nevertheless, this classification, which emphasizes natural methods (category 3), is more in line with the objectives of sustainable development, as it is based on a global bioethical approach with advantages at several levels.

- a) It emphasizes the importance of respecting the woman's body, the rhythm of her fertility (117) and the preservation

⁵ "Methods of Cycle Observation" is the French translation of "Méthodes d'observation du cycle" (MOC). It was coined, in 2016, by Dr. Sophie Saab-Tsnobiladzé, MD, FertilityCare & NaProTechnology consultant. These methods "are scientific and reliable methods for monitoring the ovulatory cycle, based on daily observation of the woman's fertility biomarkers according to a precise protocol (specific to each method). They can be used to determine whether the day which just ended was a fertile or infertile day. [...] They go beyond the notion of fertility management and are aimed at all women [...] who wish to take care of their gynecological health" (20, pp. 160-161).

- of her health [UDBHR, art. 14.2 (a)] by avoiding all unnecessary disturbances and risks.
- b) It emphasizes the principle of gender equality and the principle of equity [UDBHR, art. 10]. While the choice to use modern contraceptive methods is seen as liberating, the onus is on the woman alone to take care of everything that goes with it: medical follow-up, the commitment to take the pill on time, the stress of not forgetting, the risks and side effects involved, and so on. In this sense, promoting these modern contraceptive methods does not seem to achieve gender equality. Gender equality can only be achieved if both protagonists are involved as much as possible, in accordance with their anthropo-physiological identity, in the process deciding “freely and responsibly the number and spacing of their children” (ICPD, Principle 8 and § 7.12). Especially with MCO, woman and her partner accompanied and supported by specialized practitioners, learn and understand together the physiology of her body. The motivation and ability to live with abstinence during fertile periods (118) have as a result a strengthening of the couple’s bond (119).
 - c) It emphasizes methods that are environmentally friendly, because they do not pollute and do not affect human or environmental health. This helps to protect and promote “the interests of the present and future generations” [UDBHR, art. 2 (g), 14.2 (b), 16 and 20].
 - d) It responds to the call for health accessibility [UDBHR, art. 14.2 (a) and 15.1 (b)], especially the economic accessibility, which is a barrier for many women. This is because the majority of Physiological Methods are based on the observation of the woman’s cycle. woman’s cycle and technical assistance is affordable. Once done, it is almost for life, but regular follow-ups with certified instructors are recommended. The only element that can be costly is time, which requires commitment, discipline and a change in lifestyle.

Acknowledgments

The author would like to express his gratitude to:

- Dr. Sophie Saab-Tsnobiladzé (MD, FertilityCare & NaPro-Technology consultant) for her invaluable advice during this research and for reviewing this article.
- Mrs. Jeanine Daher for her exceptional assistance in language of this article.

References

1. Transforming our world: the 2030 Agenda for Sustainable Development. Resolution adopted by the General Assembly on 25 September 2015 [Internet]. Available from: <https://sdgs.un.org/2030agenda>
2. World Health Organization. WHO. Sexual and reproductive health and rights [Internet]. [cited 2024 Oct 9]. Available from: <https://www.who.int/health-topics/sexual-and-reproductive-health-and-rights>
3. United Nations Department of Economic and Social Affairs. World Family Planning 2022. Meeting the changing needs for family planning: Contraceptive use by age and method [Internet]. 4th ed. New York: United Nations; 2022 [cited 2023 Oct 7]. Available from: https://www.un.org/development/desa/pd/sites/www.un.org.development.desa.pd/files/files/documents/2023/Feb/undesa_pd_2022_world-family-planning.pdf
4. Festin MPR, Kiarie J, Solo J, Spieler J, Malarcher S, Van Look PFA. Moving towards the goals of FP2020 — classifying contraceptives. *Contraception* [Internet]. 2016 Oct [cited 2022 Nov 29]; 94(4):289–94. Available from: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5032916/>
5. UNDP/UNFPA/UNICEF/WHO/World Bank Special Programme of Research, Development and Research, Training in Human Reproduction (HRP). Annual technical report 2015 [Internet]. Geneva: United Nations; 2016 [cited 2022 Nov 29]. Available from: <http://apps.who.int/iris/bitstream/10665/246092/1/WHO-RHR-HRP-16.08-eng.pdf>
6. UNESCO. Universal Declaration on Bioethics and Human Rights (2005) [Internet]. Available from: <https://www.unesco.org/en/legal-affairs/universal-declaration-bioethics-and-human-rights>
7. UNESCO. Global bioethics: what for? Twentieth anniversary of UNESCO's Bioethics Programme [Internet]. Paris: Germán Solinís; 2015 [cited 2024 Oct 9]. Available from: <https://unesdoc.unesco.org/ark:/48223/pf0000231159>

8. United Nations, Department of Economic and Social Affairs. Family Planning and the 2030 Agenda for Sustainable Development. Data Booklet [Internet]. New York: United Nations; 2019 [cited 2022 Nov 15]. Available from: https://www.un.org/en/development/desa/population/publications/pdf/family/familyPlanning_DataBooklet_2019.pdf
9. World Health Organization Department of Sexual and Reproductive Health and Research (WHO/SRH), Johns Hopkins Bloomberg School of Public Health/ Center for Communication Programs (CCP), Knowledge SUCCESS. Family Planning: A Global Handbook for Providers. Evidence-based guidance developed through worldwide collaboration [Internet]. 4th ed. Geneva and Baltimore: World Health Organization and Johns Hopkins; 2022 [cited 2023 Oct 7]. Available from: <https://www.who.int/publications/i/item/9780999203705>
10. United Nations, Department of Economic and Social Affairs, Population Division. Contraceptive use by Method 2019. Data Booklet [Internet]. New York: United Nations; 2019 [cited 2022 Nov 26]. Available from: https://www.un.org/development/desa/pd/sites/www.un.org.development.desa.pd/files/files/documents/2020/Jan/un_2019_contraceptiveusebymethod_databooklet.pdf
11. United Nations. Department of Economic and Social Affairs Statistics [Internet]. 2022 [cited 2022 Nov 25]. SDG Indicators-SDG Indicators. Available from: <https://unstats.un.org/sdgs/metadata>
12. United Nations [Internet]. [cited 2022 Oct 30]. UN Population Division Data Portal. Interactive access to global demographic indicators. Available from: <https://population.un.org/dataportal/home>
13. Bellizzi S, Mannava P, Nagai M, Sobel HL. Reasons for discontinuation of contraception among women with a current unintended pregnancy in 36 low and middle-income countries. *Contraception* [Internet]. 2020 [cited 2022 Oct 30]; 101(1):26–33. Available from: <https://www.sciencedirect.com/science/article/pii/S0010782419304305>
14. SDG Metadata Translation Project [Internet]. [cited 2022 Oct 30]. Indicateur: 3.7.1. Available from: <https://worldbank.github.io/sdg-metadata/metadata/fr/3-7-1/>
15. World Health Organization. WHO. High rates of unintended pregnancies linked to gaps in family planning services: New who study [Internet]. 2019 [cited 2022 Oct 31]. Available from: <https://www.who.int/news/item/25-10-2019-high-rates-of-unintended-pregnancies-linked-to-gaps-in-family-planning-services-new-who-study>
16. Contraception Policy Atlas 2023 [Internet]. Brussels: European Parliamentary Forum (EPF) for Sexual & Reproductive Rights; 2023 [cited 2023 May 3] Available from: <https://www.epfweb.org/node/89>
17. United Nations. ICPD Programme Action [Internet]. <https://www.unfpa.org/icpd-re-design>. UNFPA; 2014 [cited 2022 Jan 10]. Available from: <https://www.unfpa.org/icpd-re-design>
18. Gautier-Lavaste C. Planification familiale naturelle. Enquête auprès d'internes en médecine générale : Connaissances, intérêts pour le sujet, enseignement à la faculté et place dans une consultation au cabinet. [Internet] [Thèse de doctorat]. [Paris]: Université René Descartes- Paris 5; 2007 [cited 2022 Nov 26].

19. Bodet A. Histoire de la contraception. De la grossesse subie à la grossesse désirée [Internet] [Thèse de doctorat]. [Angers]: Université d'Angers; 2014 [cited 2022 Nov 25]. Available from: <https://dune.univ-angers.fr/fichiers/20080073/2014P-PHA3265/fichier/3265F.pdf>
20. Vallet M, Saab-Tsnobiladzé S. Cycle féminin au naturel. Gérer sa fertilité et prendre soin de sa santé gynécologique. Paris: Leduc; 2022.
21. Creighton Model – Unleashing the power of a woman's cycle [Internet]. [cited 2024 Oct 9]. Available from: <https://creightonmodel.com/>
22. Dakoure CP bamba. L'allaitement maternel exclusif comme méthode de contraception : étude de la méthode de l'allaitement maternel et d'aménorrhée (MAMA) dans deux centres médicaux de la ville de Ouagadougou [Internet] [Thèse de doctorat]. [Angers]: Université de Ouagadougou; 2012 [cited 2022 Nov 26]. Available from: <https://beep.ird.fr/collect/uouaga/index/assoc/M13041.dir/M13041.pdf>
23. MMNFP.com [Internet]. [cited 2024 Oct 9]. The Marquette Method. Available from: <https://www.mmnfp.com/marquettenfp>
24. FEMM Health [Internet]. [cited 2024 Oct 9]. Fertility Education and Medical Management. Available from: <https://femmhealth.org/>
25. Sinapov I. BGO Software. 2024 [cited 2024 Oct 9]. What Is Femtech: Solutions and Trends. Available from: <https://www.bgosoftware.com/blog/what-is-femtech-solutions-and-trends/>
26. UN Women. Beijing Declaration and Platform for Action, Beijing +5 Political Declaration and Outcome [Internet]. 2014th ed. United Nations; 1995 [cited 2022 Jan 10]. Available from: <https://www.unwomen.org/en/digital-library/publications/2015/01/beijing-declaration>
27. Finer LB, Henshaw SK. Disparities in Rates of Unintended Pregnancy In the United States, 1994 and 2001. *Perspect Sex Reprod Health* [Internet]. 2006 [cited 2022 Oct 31]; 38(2):90–6. Available from: <https://onlinelibrary.wiley.com/doi/abs/10.1363/3809006?sid=nlm%3Apubmed>
28. Coombe J, Harris ML, Wigginton B, Loxton D, Lucke J. Contraceptive use at the time of unintended pregnancy: Findings from the Contraceptive Use, Pregnancy Intention and Decisions study. *Aust J Gen Pract* [Internet]. 2016 Nov [cited 2022 Oct 31]; 45(11):842–8. Available from: <https://www.racgp.org.au/afp/2016/november/contraceptive-use-at-the-time-of-unintended-pr-2>
29. Polis C, Bradley SEK, Bankole A, Onda T, Croft TN, Singh S. Contraceptive Failure Rates in the Developing World: An Analysis of Demographic and Health Survey Data in 43 Countries [Internet]. New York: Guttmacher Institute; 2016 Mar [cited 2022 Nov 28] Available from: <https://www.guttmacher.org/report/contraceptive-failure-rates-in-developing-world>
30. Hatcher RA, Nelson AL, Trussel J, Cwiak C, Cason P, Policar MS. Contraceptive Technology. 21st ed. Managing Contraception, LLC; 2018.
31. Frank-Herrmann P, Heil J, Gnoth C, Toledo E, Baur S, Pyper C. The effectiveness of a fertility awareness based method to avoid pregnancy in relation to a couple's sexual behaviour during the fertile time: a prospective longitudinal study. *Hum Reprod* [Internet]. 2007 [cited 2022 Nov 24]; 22(5):1310–9. Available from: <https://academic.oup.com/humrep/article/22/5/1310/2914315?login=false>

32. Qian SZ, Zhang DW, Huai-Zhi Z, Lu RK, Peng L, He CH. Evaluation of Effectiveness of Natural Fertility Regulation Programme in China - WOOMB International [Internet]. *Science of Fertility*. 2021 [cited 2022 Nov 30]. Available from: <https://woombinternational.org/science-of-fertility/evaluation-of-effectiveness-of-natural-fertility-regulation-programme-in-china/>
33. Peragallo Urrutia R, Polis CB, Jensen ET, Greene ME, Kennedy E, Stanford JB. Effectiveness of Fertility Awareness–Based Methods for Pregnancy Prevention: A Systematic Review. *Obstet Gynecol* [Internet]. 2018 [cited 2022 Nov 30]; 132(3):591–604. Available from: https://journals.lww.com/greenjournal/Abstract/2018/09000/Effectiveness_of_Fertility_Awareness_Based_Methods.8.aspx
34. Berglund Scherwitzl E, Lundberg O, Kopp Kallner H, Gemzell Danielsson K, Trussell J, Scherwitzl R. Perfect-use and typical-use Pearl Index of a contraceptive mobile app. *Contraception* [Internet]. 2017 [cited 2024 Oct 9]; 96(6):420–5. Available from: [https://www.contraceptionjournal.org/article/S0010-7824\(17\)30429-8/fulltext](https://www.contraceptionjournal.org/article/S0010-7824(17)30429-8/fulltext)
35. Bradley SEK, Polis CB, Bankole A, Croft T. Global Contraceptive Failure Rates: Who Is Most at Risk? *Stud Fam Plann* [Internet]. 2019 [cited 2022 Nov 30]; 50(1):3–24. Available from: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6594038/>
36. Hill S. *This Is Your Brain on Birth Control: The Surprising Science of Women, Hormones, and the Law of Unintended Consequences*. New York: Avery; 2019.
37. Malmborg A, Persson E, Brynhildsen J, Hammar M. Hormonal contraception and sexual desire: A questionnaire-based study of young Swedish women. *Eur J Contracept Reprod Health Care* [Internet]. 2016 [cited 2022 Dec 3]; 21(2):158–67. Available from: <https://www.tandfonline.com/doi/abs/10.3109/13625187.2015.1079609?journalCode=iejc20>
38. Battaglia C, Morotti E, Persico N, Battaglia B, Busacchi P, Casadio P. Clitoral vascularization and sexual behavior in young patients treated with drospirenone-ethinyl estradiol or contraceptive vaginal ring: a prospective, randomized, pilot study. *J Sex Med* [Internet]. 2014 Feb [cited 2023 Apr 20]; 11(2):471–80. Available from: <https://www.sciencedirect.com/science/article/abs/pii/S1743609515306792?via%3Dihub>
39. Skovlund CW, Mørch LS, Kessing LV, Lidegaard Ø. Association of Hormonal Contraception With Depression. *JAMA Psychiatry* [Internet]. 2016 Nov 1 [cited 2022 Dec 3]; 73(11):1154–62. Available from: <https://jamanetwork.com/journals/jama-psychiatry/fullarticle/2552796>
40. Skovlund CW, Mørch LS, Kessing LV, Lange T, Lidegaard Ø. Association of Hormonal Contraception With Suicide Attempts and Suicides. *Am J Psychiatry* [Internet]. 2018 Apr [cited 2022 Dec 3]; 175(4):336–42. Available from: <https://ajp.psychiatryonline.org/doi/10.1176/appi.ajp.2017.17060616>
41. Larsen SV, Mikkelsen AP, Lidegaard Ø, Frokjaer VG. Depression Associated With Hormonal Contraceptive Use as a Risk Indicator for Postpartum Depression. *JAMA Psychiatry* [Internet]. 2023 Jul 1 [cited 2023 Oct 16]; 80(7):682–9. Available from: <https://jamanetwork.com/journals/jamapsychiatry/fullarticle/2804354>
42. Arnal-Morvan B. *Pilule ou pas pilule ? Tout savoir sur les différents moyens de contraception y compris masculins*. Vergèze: Thierry Souccar; 2022.

43. Kuhlmann S, Wolf OT. Cortisol and memory retrieval in women: influence of menstrual cycle and oral contraceptives. *Psychopharmacology (Berl)* [Internet]. 2005 [cited 2023 May 5]; 183(1):65–71. Available from: <https://link.springer.com/article/10.1007/s00213-005-0143-z>
44. Bianchini F, Verde P, Colangeli S, Boccia M, Strollo F, Guariglia C. Effects of oral contraceptives and natural menstrual cycling on environmental learning. *BMC Womens Health* [Internet]. 2018 Nov 7 [cited 2023 May 5]; 18(179). Available from: <https://doi.org/10.1186/s12905-018-0671-4>
45. Nielsen SE, Ertman N, Lakhani YS, Cahill L. Hormonal contraception usage is associated with altered memory for an emotional story. *Neurobiol Learn Mem* [Internet]. 2011 Sep 1 [cited 2023 May 5]; 96(2):378–84. Available from: <https://www.sciencedirect.com/science/article/pii/S1074742711001249>
46. Rumberg B, Baars A, Fiebach J, Ladd ME, Forsting M, Senf W. Cycle and gender-specific cerebral activation during a verb generation task using fMRI: Comparison of women in different cycle phases, under oral contraception, and men. *Neurosci Res* [Internet]. 2010 Apr 1 [cited 2023 May 5]; 66(4):366–71. Available from: <https://www.sciencedirect.com/science/article/pii/S0168010209020951>
47. Marečková K, Perrin JS, Nawaz Khan I, Lawrence C, Dickie E, McQuiggan DA. Hormonal contraceptives, menstrual cycle and brain response to faces. *Soc Cogn Affect Neurosci* [Internet]. 2014 Feb 1 [cited 2023 May 5]; 9(2):191–200. Available from: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3907931/>
48. Chen KX, Worley S, Foster H, Edasery D, Roknsharifi S, Ifrah C. Oral contraceptive use is associated with smaller hypothalamic and pituitary gland volumes in healthy women: A structural MRI study. *PLOS One* [Internet]. 2021 [cited 2022 Dec 3]; 16(4):e0249482. Available from: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8059834/>
49. Brouillard A, Davignon LM, Turcotte AM, Marin MF. Morphologic alterations of the fear circuitry: the role of sex hormones and oral contraceptives. *Front Endocrinol* [Internet]. 2023 [cited 2023 Nov 11]; 14:1–22. Available from: <https://www.frontiersin.org/articles/10.3389/fendo.2023.1228504>
50. Simões TMR, Zapata CLV, Donangelo CM. Influence of hormonal contraceptives on indices of zinc homeostasis and bone remodeling in young adult women. *Rev Bras Ginecol E Obstet* [Internet]. 2015 [cited 2022 Dec 3]; 37(9):402–10. Available from: <https://pubmed.ncbi.nlm.nih.gov/26313883/>
51. Kaddah M, Le-Brech F. *Génération No Pilule*. Illustrated édition. Paris: Larousse; 2021.
52. Plu-Bureau G, Raccah-Tebeka B. La balance bénéfices-risques des contraceptions hormonales estroprogestatives. *médecine/sciences* [Internet]. 2022 [cited 2022 Nov 30]; 38(1):59–69. Available from: <https://www.medecinesciences.org/articles/medsci/abs/2022/01/msc200660/msc200660.html>
53. Lidegaard Ø, Løkkegaard E, Jensen A, Skovlund CW, Keiding N. Thrombotic Stroke and Myocardial Infarction with Hormonal Contraception. *N Engl J Med* [Internet]. 2012 Jun 14 [cited 2022 Dec 3]; 366(24):2257–66. Available from: <https://www.nejm.org/doi/10.1056/NEJMoa1111840>

54. Fairweather D, Rose NR. Women and Autoimmune Diseases. *Emerg Infect Dis* [Internet]. 2004 Nov [cited 2023 Jan 4]; 10(11):2005–11. Available from: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3328995/>
55. Bernier MO, Mikaeloff Y, Hudson M, Suissa S. Combined oral contraceptive use and the risk of systemic lupus erythematosus. *Arthritis Care Res* [Internet]. 2009 Apr 15 [cited 2023 Jan 4]; 61(4):476–81. Available from: <https://onlinelibrary.wiley.com/doi/10.1002/art.24398>
56. Williams WV. Hormonal Contraception and the Development of Autoimmunity: A Review of the Literature. *Linacre Q* [Internet]. 2017 [cited 2023 Jul 23]; 84(3):275–95. Available from: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5592309/>
57. International Agency for Research on Cancer. IARC. Pharmaceuticals. IARC Monographs on the Evaluation of Carcinogenic Risks to Humans Volume 100A [Internet]. Lyon: International Agency for Research on Cancer (IARC). World Health Organization (who); 2012 [cited 2022 Dec 3]. 435 p. Available from: <https://publications.iarc.fr/118>
58. Lidegaard Ø, Nielsen LH, Skovlund CW, Løkkegaard E. Venous thrombosis in users of non-oral hormonal contraception: follow-up study, Denmark 2001-10. *BMJ* [Internet]. 2012 [cited 2023 Jun 5]; 344:e2990. Available from: <https://www.bmj.com/content/344/bmj.e2990>
59. Mirena (levonorgestrel-releasing intrauterine system) [Internet]. 2020 Aug [cited 2022 Dec 4] Available from: https://labeling.bayerhealthcare.com/html/products/pi/Mirena_PI.pdf
60. DIU au lévonorgestrel : surcroît de grossesses extra-utérines. *Prescrire* [Internet]. 2023 [cited 2023 Nov 1]; (481):286. Available from: <https://www.prescrire.org/Fr/SummaryDetail.aspx?Issueid=481>
61. Meaidi A, Torp-Pedersen C, Lidegaard Ø, Mørch LS. Ectopic Pregnancy Risk in Users of Levonorgestrel-Releasing Intrauterine Systems With 52, 19.5, and 13.5 mg of Hormone. *JAMA* [Internet]. 2023 [cited 2023 Nov 1]; 329(11):935–7. Available from: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10031393/>
62. Tulandi T. Ectopic pregnancy: Epidemiology, risk factors, and anatomic sites. *UpToDate* [Internet]. 2023 [cited 2023 Nov 1]. Available from: <https://medilib.ir/up-to-date/show/5481>
63. Huijbregts RPH, Helton ES, Michel KG, Sabbaj S, Richter HE, Goepfert PA. Hormonal Contraception and HIV-1 Infection: Medroxyprogesterone Acetate Suppresses Innate and Adaptive Immune Mechanisms. *Endocrinology* [Internet]. 2013 [cited 2024 Oct 17]; 154(3):1282. Available from: <https://pmc.ncbi.nlm.nih.gov/articles/PMC3578997/>
64. Wand H, Ramjee G. The effects of injectable hormonal contraceptives on HIV seroconversion and on sexually transmitted infections. *AIDS* [Internet]. 2012 [cited 2024 Oct 17]; 26(3):375. Available from: https://journals.lww.com/aidsonline/fulltext/2012/01280/the_effects_of_injectable_hormonal_contraceptives.13.aspx
65. Roland N, Neumann A, Hoisnard L, Zureik M, Weill A. Utilisation de progestatifs et risque de méningiome intracrânien: une étude cas-témoins à partir des données du système national des données de santé (SNDS) [Internet]. Saint-Denis: EPI-PHARE – Groupement d'intérêt scientifique (GIS) ANSM-CNAM; 2023 [cited 2023

- Jun 30] Available from: <https://ansm.sante.fr/uploads/2023/07/21/20230721-rapport-epiphare-progestatifs-meningiomes-22-06-2023.pdf>
66. Roland N, Neumann A, Hoisnard L, Duranteau L, Froelich S, Zureik M. Use of progestogens and the risk of intracranial meningioma: national case-control study. *BMJ* [Internet]. 2024 Mar 27 [cited 2024 Mar 28]; 384:1–13. Available from: <https://www.bmj.com/content/384/bmj-2023-078078>
 67. Sweeney C, Giuliano A, Baumgartner K, Byers T, Herrick J, Edwards S. Oral, injected and implanted contraceptives and breast cancer risk among U.S. Hispanic and non-Hispanic white women. *Int J Cancer* [Internet]. 2007 [cited 2022 Dec 5]; 121(11):2517–23. Available from: <https://onlinelibrary.wiley.com/doi/abs/10.1002/ijc.22970>
 68. Fitzpatrick D, Pirie K, Reeves G, Green J, Beral V. Combined and progestagen-only hormonal contraceptives and breast cancer risk: A UK nested case-control study and meta-analysis. *PLOS Med* [Internet]. 2023 Mar 21 [cited 2023 Mar 26]; 20(3):e1004188. Available from: <https://journals.plos.org/plosmedicine/article?id=10.1371/journal.pmed.1004188>
 69. Yland J, Bresnick K, Hatch E, Wesselink A, Mikkelsen E, Rothman K. Pre gravid contraceptive use and fecundability: prospective cohort study. *BMJ* [Internet]. 2020 Nov 11 [cited 2023 Jan 5]; 371:m3966. Available from: <https://www.bmj.com/content/371/bmj.m3966>
 70. Goh T, Hariharan M, Tan C. A longitudinal study of serum iron indices and haemoglobin concentration following copper-IUD insertion. *Contraception* [Internet]. 1980 Oct 1 [cited 2022 Dec 5]; 22(4):389–95. Available from: [https://www.contraceptionjournal.org/article/0010-7824\(80\)90024-4/abstract](https://www.contraceptionjournal.org/article/0010-7824(80)90024-4/abstract)
 71. Borghei A, Qorbani M, Borghei NS, Kazeminejad V, Seifi F. Effects of IUD on iron status in IUD users in Gorgan, Iran. *Med J Islam Repub Iran* [Internet]. 2011 Nov 10 [cited 2022 Dec 5]; 25(3):131–5. Available from: <http://mjiri.iums.ac.ir/article-1-401-en.html>
 72. Royer A, Sharman T. Copper Toxicity. In: *StatPearls* [Internet]. Treasure Island (FL): StatPearls Publishing; 2023 [cited 2023 May 3]. Available from: <http://www.ncbi.nlm.nih.gov/books/NBK557456/>
 73. Kim SK, Romero R, Kusanovic JP, Erez O, Vaisbuch E, Mazaki-Tovi S. The prognosis of pregnancy conceived despite the presence of an intrauterine device (IUD). *J Perinat Med* [Internet]. 2010 [cited 2022 Dec 19]; 38(1):45–53. Available from: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3418877/>
 74. Beksinska M, Issema R, Beesham I, Lalbahadur T, Thomas K, Morrison C, et al. Weight change among women using intramuscular depot medroxyprogesterone acetate, a copper intrauterine device, or a levonorgestrel implant for contraception: Findings from a randomised, multicentre, open-label trial. *EClinicalMedicine* [Internet]. 2021 Apr 6 [cited 2023 Jan 10]; 34:100800. Available from: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8056402/>
 75. Birnbach M, Lehmann A, Naranjo E, Finkbeiner M. A condom's footprint - life cycle assessment of a natural rubber condom. *Int J Life Cycle Assess* [Internet]. 2020 Jun 1 [cited 2023 Jan 2]; 25(6):964–79. Available from: <https://link.springer.com/article/10.1007/s11367-019-01701-y>

76. Chaddad F, Mello FAO, Tayebi M, Safanelli JL, Campos LR, Amorim MTA, et al. Impact of mining-induced deforestation on soil surface temperature and carbon stocks: A case study using remote sensing in the Amazon rainforest. *J South Am Earth Sci* [Internet]. 2022 Nov 1 [cited 2023 Sep 8]; 119:103983. Available from: <https://www.sciencedirect.com/science/article/pii/S089598112200270X>
77. Jawjit W, Pavasant P, Kroeze C, Tuffrey J. Evaluation of the potential environmental impacts of condom production in Thailand. *J Integr Environ Sci* [Internet]. 2021 Jan 1 [cited 2023 Jan 2]; 18(1):89–114. Available from: <https://www.tandfonline.com/doi/full/10.1080/1943815X.2021.1949354>
78. Dong D, van Oers L, Tukker A, van der Voet E. Assessing the future environmental impacts of copper production in China: Implications of the energy transition. *J Clean Prod* [Internet]. 2020 Nov 20 [cited 2023 Sep 8]; 274:122825. Available from: <https://www.sciencedirect.com/science/article/pii/S0959652620328705>
79. Adetunji C, Olaniyan O, Anani O, Inobeme A, Mathew J. Environmental Impact of Polyurethane Chemistry. In: *Polyurethane Chemistry: Renewable Polyols and Iso-cyanates* [Internet]. 2021; 393–411. Available from: https://www.researchgate.net/publication/351811523_Environmental_Impact_of_Polyurethane_Chemistry
80. Bergman A, Brandt I, Brouwer B, Harisson P, Holmes P, Humfrey C, et al. European workshop on the impact of endocrine disrupters on human health and wildlife. Reports of proceedings [Internet]. Weybridge, UK: European Commission, European Environment Agency, World Health Organisation, European Office; 1996 Dec [cited 2023 Jan 3] p. 125. Report No.: CGNA17549ENC. Available from: http://www.iehconsulting.co.uk/IEH_Consulting/IEHCPubs/EndocrineDisrupters/WEY-BRIDGE.pdf
81. Tyler CR, Jobling S. Roach, Sex, and Gender-Bending Chemicals: The Feminization of Wild Fish in English Rivers. *BioScience* [Internet]. 2008 Dec 1 [cited 2022 Mar 21];58(11):1051–9. Available from: <https://academic.oup.com/bioscience/article/58/11/1051/264727>
82. Minier C, Caltot G, Leboulanger F, Hill EM. An investigation of the incidence of intersex fish in Seine-Maritime and Sussex region. *Analisis* [Internet]. 2000 Nov 1 [cited 2023 Jan 2];28(9):801–6. Available from: <https://analisi.edpsciences.org/articles/analisi/abs/2000/09/minier/minier.html>
83. Jobling S, Beresford N, Nolan M, Rodgers-Gray T, Brighty GC, Sumpter JP, et al. Altered Sexual Maturation and Gamete Production in Wild Roach (*Rutilus rutilus*) Living in Rivers That Receive Treated Sewage Effluents. *Biol Reprod* [Internet]. 2002 Feb 1 [cited 2023 Jan 4];66(2):272–81. Available from: <https://academic.oup.com/biolreprod/article/66/2/272/2723352>
84. Qin X, Lai KP, Wu RSS, Kong RYC. Continuous 17 α -ethinylestradiol exposure impairs the sperm quality of marine medaka (*Oryzias melastigma*). *Mar Pollut Bull* [Internet]. 2022 Oct 1 [cited 2023 Jan 6];183:114093. Available from: <https://www.sciencedirect.com/science/article/pii/S0025326X22007755>
85. Saaristo M, Johnstone CP, Xu K, Allinson M, Wong BBM. The endocrine disruptor, 17 α -ethinyl estradiol, alters male mate choice in a freshwater fish. *Aquat Toxicol* [Internet]. 2019 Mar 1 [cited 2023 Jan 6];208:118–25. Available from: <https://www.sciencedirect.com/science/article/pii/S0166445X18309408>

86. Kidd KA, Blanchfield PJ, Mills KH, Palace VP, Evans RE, Lazorchak JM, et al. Collapse of a fish population after exposure to a synthetic estrogen. *Proc Natl Acad Sci* [Internet]. 2007 May 22 [cited 2023 Jan 2];104(21):8897–901. Available from: <https://www.pnas.org/doi/10.1073/pnas.0609568104>
87. Margel D, Fleshner NE. Oral contraceptive use is associated with prostate cancer: an ecological study. *BMJ Open* [Internet]. 2011 Jan 1 [cited 2023 Jan 6];1(2):e000311. Available from: <https://bmjopen.bmj.com/content/1/2/e000311>
88. Bonkhoff H. Estrogen receptor signaling in prostate cancer: Implications for carcinogenesis and tumor progression. *The Prostate* [Internet]. 2018 [cited 2023 Jan 10];78(1):2–10. Available from: <https://onlinelibrary.wiley.com/doi/abs/10.1002/pros.23446>
89. Rolland M, Le Moal J, Wagner V, Royère D, De Mouzon J. Decline in semen concentration and morphology in a sample of 26 609 men close to general population between 1989 and 2005 in France. *Hum Reprod* [Internet]. 2013 Feb 1 [cited 2023 Jan 4];28(2):462–70. Available from: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4042534/>
90. Marques-Pinto A, Carvalho D. Human infertility: are endocrine disruptors to blame? *Endocr Connect* [Internet]. 2013 Sep 17 [cited 2023 Jan 13];2(3):R15–29. Available from: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3845732/>
91. Waller DK, Gallaway MS, Taylor LG, Ramadhani TA, Canfield MA, Scheuerle A, et al. Use of Oral Contraceptives in Pregnancy and Major Structural Birth Defects in Offspring. *Epidemiology* [Internet]. 2010 Mar [cited 2023 Jan 10];21(2):232–93. Available from: https://journals.lww.com/epidem/Fulltext/2010/03000/Use_of_Oral_Contraceptives_in_Pregnancy_and_Major.11.aspx
92. Delbès G, Levacher C, Habert R. Estrogen effects on fetal and neonatal testicular development. *Reproduction* [Internet]. 2006 Oct 1 [cited 2023 Feb 15];132(4):527–38. Available from: <https://rep.bioscientifica.com/view/journals/rep/132/4/1320527.xml>
93. Lyall K, Pauls DL, Santangelo S, Spiegelman D, Ascherio A. Maternal Early Life Factors Associated with Hormone Levels and the Risk of Having a Child with an Autism Spectrum Disorder in the Nurses Health Study II. *J Autism Dev Disord* [Internet]. 2011 May 1 [cited 2023 Oct 10];41(5):618–27. Available from: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3494408/>
94. Strifert K. An epigenetic basis for autism spectrum disorder risk and oral contraceptive use. *Med Hypotheses* [Internet]. 2015 Dec 1 [cited 2023 Oct 10];85(6):1006–11. Available from: <https://www.sciencedirect.com/science/article/pii/S0306987715003230>
95. Baker D, Keogh S, Luchsinger G, Roseman M, Sedgh G, Solo J. Seeing the Unseen: The case for action in the neglected crisis of unintended pregnancy [Internet]. New York: United Nations Population Fund; 2022 [cited 2022 Oct 26] p. 160. Available from: <https://www.unfpa.org/publications/seeing-the-unseen>
96. Hernandez JH, Babazadeh S, Anglewicz PA, Akilimali PZ. As long as (I think) my husband agrees...: role of perceived partner approval in contraceptive use among couples living in military camps in Kinshasa, DRC. *Reprod Health* [Internet]. 2022

- Jan 12 [cited 2023 Aug 3];19(1):6. Available from: <https://reproductive-health-journal.biomedcentral.com/articles/10.1186/s12978-021-01256-y>
97. Kavanaugh ML, Lindberg LD, Frost J. Factors influencing partners' involvement in women's contraceptive services. *Contraception* [Internet]. 2012 Jan 1 [cited 2023 Aug 3];85(1):83–90. Available from: <https://www.contraceptionjournal.org/article/S0010-7824%2811%2900203-4/fulltext>
 98. Cadiergues D. La connaissance des hommes sur la contraception: étude quantitative auprès d'hommes de 15-55 ans [Thèse d'exercice]. [France]: Université Paris Diderot - Paris 7 (1970-2019). UFR de médecine; 2015.
 99. Lewis DA, Martins SL, Gilliam ML. Partner Roles in Contraceptive Use: What Do Adolescent Mothers Say? *J Pediatr Adolesc Gynecol* [Internet]. 2012 Dec [cited 2023 Aug 3]; 25(6):396–400. Available from: <https://www.em-consulte.com/article/766999/tableaux/partner-roles-in-contraceptive-use-what-do-adolesc>
 100. Masih N. Gender Disparities in Reproductive Health and Family Planning Choices. In: *Sustainable Development Through Gender Equality*. New Delhi: Pentagon Press; 2018. pp. 48-57.
 101. Anawalt B, Roth M, Ceponis J, Surampudi V, Amory J, Swerdloff R. Combined nesterone–testosterone gel suppresses serum gonadotropins to concentrations associated with effective hormonal contraception in men. *Andrology* [Internet]. 2019 [cited 2023 Aug 6]; 7(6):878–87. Available from: <https://onlinelibrary.wiley.com/doi/abs/10.1111/andr.12603>
 102. Nieschlag E. Use of testosterone alone as hormonal male contraceptive. *Basic Clin Androl* [Internet]. 2012 Sep [cited 2023 Aug 6]; 22(3):136–40. Available from: <https://bacandrology.biomedcentral.com/articles/10.1007/s12610-012-0187-y>
 103. Yuen F, Thirumalai A, Pham C, Swerdloff R, Anawalt B, Liu P. Daily Oral Administration of the Novel Androgen 11 β -MNTDC Markedly Suppresses Serum Gonadotropins in Healthy Men. *J Clin Endocrinol Metab* [Internet]. 2020 Jan 24 [cited 2023 Aug 6]; 105(3):e835–47. Available from: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7049261/>
 104. Thirumalai A, Ceponis J, Amory J, Swerdloff R, Surampudi V, Liu P. Effects of 28 Days of Oral Dimethandrolone Undecanoate in Healthy Men: A Prototype Male Pill. *J Clin Endocrinol Metab* [Internet]. 2019 Feb 1 [cited 2023 Aug 6]; 104(2):423–32. Available from: <https://academic.oup.com/jcem/article/104/2/423/5105935?login=false>
 105. Cicchini-blot C. La contraception testiculaire thermique (CTT) [Internet]. Biogroup. 2022 [cited 2023 Aug 6]. Available from: <https://biogroup.fr/actualites/contraception-testiculaire-thermique-ctt/>
 106. A non-hormonal pill could soon expand men's birth control options [Internet]. 2022 [cited 2023 Aug 6]. Available from: <https://www.youtube.com/watch?v=GsbQ9Obgv1Y>
 107. American Chemical Society. ACS. American Chemical Society. 2022 [cited 2023 Aug 6]. A non-hormonal pill could soon expand men's birth control options. Available from: <https://www.acs.org/pressroom/newsreleases/2022/march/non-hormonal-pill-could-soon-expand-mens-birth-control-options.html>

108. Chang Z, Qin W, Zheng H, Schegg K, Han L, Liu X, et al. Triptonide is a reversible non-hormonal male contraceptive agent in mice and non-human primates. *Nat Commun* [Internet]. 2021 Feb 23 [cited 2023 Aug 6]; 12:1253. Available from: <https://pubmed.ncbi.nlm.nih.gov/33623031/>
109. Colagross-Schouten A, Lemoy MJ, Keesler RI, Lissner E, VandeVoort CA. The contraceptive efficacy of intravas injection of VasalgeTM for adult male rhesus monkeys. *Basic Clin Androl* [Internet]. 2017 Feb 7 [cited 2023 Aug 6]; 27(1):4. Available from: <https://pubmed.ncbi.nlm.nih.gov/28191316/>
110. Khliwani B, Badar A, Ansari A, Lohiya N. RISUG[®] as a male contraceptive: journey from bench to bedside. *Basic Clin Androl*. *Basic Clin Androl* [Internet]. 2020 Feb 13 [cited 2022 Oct 26]; 30(2). Available from: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7017607/>
111. Anderson P, Bolton D, Lawrentschuk N. Pd42-08 preliminary results of a first in human dose-ranging clinical trial of adam[®], a nonhormonal hydrogel-based male contraceptive. *J Urol* [Internet]. 2023 Apr [cited 2023 Jun 15]; 209(Supplement 4):e1114. Available from: <https://www.auajournals.org/doi/abs/10.1097/JU.0000000000003352.08>
112. O'rand M, Widgren E, Sivashanmugam P, Richardson R, Hall S, French F. Reversible immunocontraception in male monkeys immunized with eppin. *Science* [Internet]. 2004 Nov 12 [cited 2023 Aug 6]; 306(5699):1189–90. Available from: https://www.science.org/doi/10.1126/science.1099743?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%20%20pubmed
113. Mariani NAP, Camara AC, Silva AAS, Raimundo TRF, Andrade JJ, Andrade AD. Epididymal protease inhibitor (EPPIN) is a protein hub for seminal vesicle-secreted protein SVS2 binding in mouse spermatozoa. *Mol Cell Endocrinol* [Internet]. 2020 Apr 15 [cited 2023 Aug 6]; 506:110754. Available from: <https://www.science-direct.com/science/article/pii/S030372072030054X>
114. Scendoni R, Cingolani M, Cembriani F, Fedeli P, Tambone V, Terranova C. Over-the-counter emergency contraception in Italy: ethical reflections and medico-legal issues. *Front Glob Womens Health* [Internet]. 2023 Sep 18 [cited 2024 Oct 19]; 4. Available from: <https://www.frontiersin.org/journals/global-womens-health/articles/10.3389/fgwh.2023.1205208/full>
115. Mozzanega B, Gizzo S, Di Gangi S, Cosmi E, Nardelli GB. Ulipristal Acetate: Critical Review About Endometrial and Ovulatory Effects in Emergency Contraception. *Reprod Sci* [Internet]. 2014 Jun 1 [cited 2024 Oct 19]; 21(6):678–85. Available from: <https://doi.org/10.1177/1933719113519178>
116. Gómez-Elías MD, May M, Munuce MJ, Bahamondes L, Cuasnicú PS, Cohen DJ. A single post-ovulatory dose of ulipristal acetate impairs post-fertilization events in mice. *Mol Hum Reprod* [Internet]. 2019 May 1 [cited 2024 Oct 19]; 25(5):257–64. Available from: <https://doi.org/10.1093/molehr/gaz013>
117. Ecochard R, Garmier-Billard M, Iwaz J. The Menstrual Cycle Phases Are Like “Body Seasons.” *Insights Anthropol* [Internet]. 2019 Sep 7 [cited 2023 Mar 3]; 3(2). Available from: <https://scholars.direct/Articles/anthropology/iap-3-022.php?jid=anthropology>

118. Ecochard R, Pinguet F, Ecochard I, De Gouvello R, Guy M, Huy F. Analyse des échecs de la planification familiale naturelle. A propos de 7007 cycles d'utilisation. *Contracept Fertil Sex*. 1998;26(4):291–6.
119. Manhart MD, Fehring RJ. The Association of Family Planning Methods With the Odds of Divorce Among Women in the 2015–2019 National Survey of Family Growth. *J Divorce Remarriage* [Internet]. 2023 Jan 2 [cited 2023 Jul 14];64(1):55–66. Available from: <https://www.tandfonline.com/doi/full/10.1080/10502556.2023.2179837>

This work is under international License Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0)

